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Abstract
Background: Left ventricular thrombus(LVT] formation is a frequent complication in patients with acute anterior
myocardial infarction(MI). LVT is associated with increased risk of embolism and higher mortality rates after acute
MI. Anticardiolipin antibodies (ACA) are immunoglobulins that react with phospholipid-binding proteins interfering
with the prothrombin activator complex. The effects of phospholipids on pathophysiology of cardiovascular
thrombotic events are well known. In this study, we aimed to evaluate the importance of clinical and biochemical
parameters including anticardiolipin antibodies on left ventricular thrombus formation after acute anterior MI.
Methods and Results: Seventy patients with a first anterior AMI were prospectively and consecutively enrolled.
Patients with previous MI, autoimmune disease, collagen vascular disease and arterial or venous thrombosis history
were excluded from this study. At the time of hospitalization, key demographic and clinical characteristics were
collected including age, gender, ethanol intake and presence of traditional risk factors for atherosclerosis
(hypertension, diabetes, smoking, hyperlipidemia, positive family history). Patients were evaluated for
echocardiographic data, blood chemistry and ACA. Two-dimensional and Doppler echocardiographic examinations
were performed in all patients within the first week and at 14 days after MI. LV thrombus was detected in 30
(42.8%) patients. ACA IgM levels were significantly higher in the patient group with LV thrombus than in the group
without thrombus (12.44 ±4.12 vs. 7.69 ± 4.25 mpl, p = 0,01). ACA IgG levels were also found higher in the group
with LV thrombus (24.2 ± 7.5 vs.17.98 ± 6.45 gpl, p = 0.02). Multivariate analyses revealed diabetes mellitus, higher
WMSI, lower MDT and higher ACA IgM and higher ACA IgG levels as independent predictors of left ventricular
thrombus formation.
Conclusions: Our data demonstrate that beside the low ejection fraction, lower MDT and higher wall motion
score index, modestly elevated ACA IgM and ACA IgG levels are associated with LV thrombus formation in patients
with anterior MI.
Introduction
Left ventricular thrombus(LVT) formation is a frequent
complication in patients with acute anterior myocardial
infarction(MI). Left ventricular thrombus is associated
with increased risk of embolism. Higher mortality rates
have been reported in patients with LVT after acute MI,
especially when these develop within the first 48 hours
after infarction [1,2]. Although great majority of patients
with LVT have large anterior infarcts with depressed
global left ventricular systolic function, this is not the
rule. Thrombi can also be found in some small apical
infarcts with good global left ventricular systolic func-
tion and rarely in some inferior infarcts [3]. These facts
indicate the complex nature of LVT formation. Factors
other than infarct size and site may play role in develop-
ment of LVT. Doppler derived mitral E wave decelera-
tion time (MDT) has been found to be associated with
LVT in some studies [4].
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lins that react with phospholipid-binding proteins inter-
fering with the prothrombin activator complex. The
effects of phospholipids on pathophysiology of venous
and cardiovascular thrombotic events are well known.
ACA levels have been found to be higher in young
patients with coronary artery disease and proposed to
be a risk factor in some studies [5]. ACA levels have
also been found higher in patients with acute MI [5-8].
The question of whether anticardiolipin antibodies can
be induced in response to tissue necrosis that occurs in
myocardial infarction is unknown. There are some
reports of patients with LVT and high ACA titers with-
out MI and with normal left ventricular systolic function
[9-11]. There is no detailed study evaluating the effects
of ACA IgM and ACA IgG levels on development of
left ventricular thrombus formation in patients with
acute anterior myocardial infarction.
As LVT formation has a complex nature, we aimed to
evaluate the factors associated with LVT formation in a
group of patients with their first anterior wall MI who
recieved different kinds of therapies. We also aimed to
evaluate the importance of anticardiolipin antibodies on
LVT formation after acute anterior wall MI in a popula-
tion who did not present features of antiphospholipid
syndrome(APS). By selecting this population, we aimed
to evaluate if modest increase in these antibody levels
associate with LVT formation or not. We also tried to
determine if ACA levels are higher after an acute event
(MI).
Methods
Seventy patients with a first anterior AMI were prospec-
tively and consecutively enrolled. Patients were required
to meet the following criteria: (1) age <70 years, (2)
chest pain lasting >30 minutes, (3) more than 2 mm ST
segment elevation at least in 2 consecutive anterior pre-
cordial leads of the electrocardiogram(ECG),(4) initial
echocardiogram performed within 48 hours following
admission.
Patients with previous MI, autoimmune disease, col-
lagen vascular disease, arterial or venous thrombosis his-
tory,thrombotic hematological disorders, history of heart
failure were excluded from the study. By excluding these
subjects, we aimed to compose a homogenous patient
group to avoid misinterpretation caused by results of
patients with those pathologies. In addition, patients
with atrial fibrillation, aortic stenosis, renal dysfunction
(history of renal failure or serum creatine level ≥1.3 mg/
dl), hepatic dysfunction(history of hepatic disease or
serum transaminase level elevations greater than 2 times
the upper limit of normal), patients with permanent
pacemakers and patients with low quality echocardi-
graphic images were also excluded from the study.
At the time of hospitalization, key demographic and
clinical characteristics were collected including age,
gender, ethanol intake and presence of traditional risk
factors for atherosclerosis (hypertension, diabetes,
smoking, hyperlipidemia, positive family history). A
complete diagnostic evaluation was performed for each
patient; this included blood chemistry, blood cell
counts, erythrocyte sedimentation rate, fibrinogen
levels, ACA IgM and ACA IgG levels, coagulation
panel, ECG and chest × ray.
Therapy
Thrombolytic therapy either t-PA(accelerated t-PA pro-
tocol;15 mg intravenous bolus, followed by 0.75 mg/kg
infused over the next 60 minutes) or streptokinase
(1500000 unit infused over 60 minutes) were adminis-
t e r e dt o4 0o f7 0p a t i e n t s ( 2 6s t r e p t o k i n a s e ,1 4t - P A ) .
Primary percutaneous coronary intervention(PCI) with
stenting was performed to 5 patients. After prompt clin-
ical and laboratory evaluation, reperfusion therapy was
not given to other patients due to late admission. Acetyl
Salicylic Acid(ASA) (160-300 mg), heparin, beta blockers
and angiotensin converting enzyme(ACE) inhibitors
were given to all patients. Statins, nitrates and positive
inotropic agents were administrated if neccessary. War-
farin was subsequently administered if LVT was present
on echocardiography and there was no contraindication
for anticoagulant therapy. Patients were followed at out-
patient clinic on a monthly basis after hospital
discharge.
Echocardiography
Echocardiography was performed within 48 hours of
admission with an Acusone 128 XP/5 ultrasound system
with 3.5 MHz transducer(Mountain view, CA. USA.)
The procedure was repeated on day 4, day7 and day 14
of hospitalization. The images were recorded and ana-
lyzed by 2 independent cardiologist, who were blinded
to each others interpretation. The diagnosis of left ven-
tricular thrombus was made when an echodense mass
was visible throughout the cardiac cycle in at least two
echocardiographic views with associated asynergy(akin-
esis or dyskinesis) of the adjacent myocardium [12,13]
and with a distinct magrin from the left ventricular wall
detected within the left ventricular cavity. And if both of
the cardiologists were completely agree about the pre-
sence of thrombus.
The Wall Motion Score Index (WMSI) was obtained
semiquantitatively on initial echocardiographic examina-
tion by dividing the left ventricule to 16 segments as
proposed by the American Society of Echocardiography
[14]. Segmental wall motion was graded as follows: nor-
mal motion at rest(score = 1); hypokinetic-marked
reduction in endocardial motion and systolic thickening
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and systolic thickening(score = 3); and dyskinetic-para-
doxical wall motion away from the centre of the left
ventricle in systole(score = 4) [15]. The WMSI was cal-
culated by summation of individual segment scores
divided by the number of interpreted segments. Left
ventricular ejection fraction was estimated using Simp-
son’s modified biplane method [16].
Left ventricular diastolic filling patterns were deter-
mined by the mitral inflow pulsed-wave Doppler exami-
nation with a 2.5-MHz transducer. In the apical 4-
chamber view, the Doppler sample volume was placed
in the middle of the LV inflow tract 1 cm below the
plane of mitral annulus between the mitral leaflet tips,
where maximal flow velocity in early diastole was
recorded. Special care was taken to align the sample
volume as close to perpendicular as possible to the
mitral annular plane. From Doppler spectra of 3 to 5
consecutive cardiac cycles, average values were calcu-
lated for the following transmitral parameters: peak
early(E) and late(A) transmitral filling velocities, their
ratio(E/A), and the deceleration time of E wave velocity
(MDT).
Measurement of Antibodies
All the tests were done in duplicate with sera stored at
-70°C, and mean value was obtained. Determination of
ACL antibodies was performed by standarized ELISA
for both IgG and IgM isotypes as previously described
[17]. Results are expressed as GPL units for IgG and
MPL units for IgM ACL antibodies with 1 GPL or MPL
unit being equivalent to 1 μg/ml of an affinity-purified
Standard [18]. All the tests met the guality control stan-
dards as determined by the manufacturer. Referrence
ranges of ACA assay in our study for ACA IgM was
<9.8 MPLU/ml and <13.3 MPLU/ml for IgG. Values
above these cut-off points were considered as elevated
levels in this study.
Coronary Angiography
Coronary angiography was performed to 46 of 70
patients during hospitalization. The angiographic find-
ings were graded according to the American Heart
Association (AHA) classification [19], in which signifi-
cant coronary stenosis is defined as ≥75% narrowing of
the major epicardial artery.
Statistical Analyses
Data were presented as mean ± standard deviation. The
Chi-square test was used for the comparison of non-
parametric data and T-test was used to compare contin-
uous variables. The Cox regression model was used to
identify variables associated with thrombus formation
(univariate analysis). Step-wise multiple regression
analysis was performed to determine the correlation
between left ventricular thrombus formation and each
independent variable
P value of <0.05 with 95% confidence interval was
considered statistically significant. All tests were per-
formed with SPSS(Statistical Package for Social Sciences,
Chicago, IL,USA) for Windows 10.0.
The study complies with the Declaration of Helsinki
and the Ethics Committee of local university faculty of
medicine has approved the research protocol. Informed
consent has been obtained from all included subjects.
Results
LVT was detected in 30 of 70 patients(42.8%). Patients
were divided into two groups according to the presence
of LVT detected by echocardiography(Group 1 with
LVT, Group 2 without LVT). The cumulative percen-
tage of identified thrombus in each echocardiographic
examination was 16.66%(5) within 48 hours; 50%(15)
within 96 hours; 80%(24) at 1 week and 100%(30) at 2
weeks.
There were no significant differences between two
groups in terms of age, gender, hyperlipidemia, smoking,
family history of coronary artery disease and hospitaliza-
tion duration. Baseline characteristics of patients were
shown on Table 1. Previous history of hypertension was
significantly higher in the patient group without throm-
bus(p = 0.02), whereas history of diabetes mellitus was
significantly lower in this group(p = 0.04).
Peak CPK levels were significantly higher in patient
group with left ventricular thrombus than without
thrombus (4170 ± 1250.60 U/L, 2580.24 ± 1468.25 U/L,
respectively p < 0.001, Table 2).
Mean left ventricular WMSI of patients with left ven-
tricular thrombus was significantly higher than patients
without thrombus (2.17 ± 0,21 and 1.81 ± 0.25 respec-
tively, p < 0.001, Table 2). Initial (Day 1) ejection frac-
tions (EF) of patient group with left ventricular
Table 1 Baseline characteristics of patients
Without thrombi With thrombi p value
Number of patients 40(%56.2) 30(%42.8) NS
Age(y), mean ± SD 52 ± 12 56 ± 15 NS
Female (%) 4(%11.76) 2(%6.66) NS
Male (%) 30(%88.23) 28(%93.33) NS
Hypertension(%) 14(%41) 5(%16) = 0,02
Hyperlipidemia(%) 20(%58) 20(%66) NS
Diabetes (%) 1(%2.9) 15(%23) = 0,04
Smoking(%) 27(%79) 26(%86) NS
Hospitalization duration 7 ± 2 8 ± 2 NS
KILLIP class at admision 1.47 ± 0.92 2.31 ± 1 = 0.04
NS = Non significant.
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without thrombus (30 ± 5.3%and 41 ± 3.7% respectively,
p = 0.001, Table 2). Doppler-derived mitral E wave
deceleration time(MDT) was significantly lower in
patients with LVT than without LVT(127.34 ± 39.07 ms
versus 155.26 ± 44.61 ms respectively, p = 0.007).
ACA IgM levels were significantly higher in the
patient group with LV thrombus than in the group
without thrombus (12.44 ± 4.12 vs. 7.69 ± 4.25 mpl, p =
0,01). ACA IgG levels were also found higher in the
group with LV thrombus (24.2 ± 7.5 vs.17.98 ± 6.45 gpl,
p = 0.02).
Thrombolytic therapy has been administrated to
40 patients. LVT was observed in 16 of them. Reperfu-
sion therapy was not given to 25 patients, and LVT was
observed in 12 of them. Five patients have undergone
primary PCI and in 2 of them LVT was developed.
These findings were statistically nonsignificant.
46 patients have undergone diagnostic coronary angio-
graphy(66%). Significant coronary stenosis was defined
as ≥75% narrowing of a major epicardial artery. Accord-
ing to this criteria 19(41%) of patients had single vessel
disease, 18(39%) had 2-vessel disease and 8(17%) had 3-
vessel disease and one patient had completely normal
coronary arteries. LVT was observed in this patient with
normal coronary arteries. LVT was observed in 7 of 19
(37%, p = nonsignificant) patients with single vessel dis-
ease, 9 of 18(50%, p = nonsignificant) patients with 2-
vessel disease and 7 of 8(87.5%, p < 0.001) patients with
3-vessel disease.
Univariate analysis(Table 3) showed that LV thrombus
formation was associated with a higher ACA IgM levels
(beta = 0.02, p = 0.01), a higher ACA IgG levels (beta =
1.75, p = 0.02), a lower initial ejection fraction (beta =
0.04, p = 0,001), lower MDT(beta = 0.03, p = 0.02) and
a higher initial wall motion score index (beta = -0.86,
p = 0.01).
In multivariate analyses(Table 4), diabetes mellitus
(odds ratio, 1.26; 95% confidence interval, 1.24 to 5.29;
p = 0.03), higher WMSI(odds ratio, 1.95; 95%
confidence interval 1.33 to 6.57; p = 0.001), lower MDT
(odds ratio, 1.67; 95% confidence interval 1.49 to 7.53; p
= 0.001) and higher ACA IgM (odds ratio, 1.27; 95%
confidence interval, 1.23 to 4.19; p = 0.04) and higher
ACA IgG levels(odds ratio, 1.41: 95% confidence inter-
val, 1.34 to 4.42 p = 0.03) were independent predictors
of left ventricular thrombus formation.
Four embolic cerebrovascular accidents developed in
the group with LVT during the 6-month follow-up per-
iod eventhough they were under ASA and warfarin ther-
apy. Two of them died. Ischeamic cerebrovascular event
was not observed in patient group without thrombus.
Six-month mortality of patients was 16.66%(5/30) with
LVT, and 5%(2/40) without LVT(P < 0.001).
Discussion
Left ventricular thrombosis is one of the most often and
devastating complication of acute myocardial infarction.
In different studies, incidence of left ventricular throm-
bosis was found to be between 28% and 54%
[1,12,20-22]. In our study, the incidence of left ventricu-
lar thrombi was found to be 42.85%. This value seems
to be higher than expected. Currently preferred reperfu-
sion strategy for acute MI is PCI. However only a
Table 2 Biochemical and echocardiographic findings
between two groups
Without thrombi With thrombi p value
CPK(peak) 2580.24 ± 1468.25 U/L 4170 ± 1250.60 U/L < 0.001
WMSI(day 1) 1.81 ± 0.25 2.17 ± 0,21 < 0.001
EF(%,day 1) 41 ± 3.7 30 ± 5.3 = 0.001
MDT 155.26 ± 44.61 ms 127.34 ± 39.07 ms = 0.007
ACA IgM 7.69 ± 4.25 mpl 12.44 ± 4.12 mpl = 0.01
ACA IgG 17.98 ± 6.45 gpl 24.2 ± 7.5 gpl = 0.02
WMSI = Wall motion score index; EF = Ejection fraction; CPK = Creatine
phospho kinase; MDT = Mitral E wave Deceleration Time; ACA=Anticardiolipin
antibody; NS = Non significant.
Table 3 Predictors of thrombus formation according to
univariate analysis
Beta P value
Age 0.001 NS
Gender(F/M) 0.002 NS
Hypertension -0.84 0,02
Hyperlipidemia 1.4 NS
Diabetes 0.9 0,04
Smoking 1.34 NS
WMSI(day 1) -0.86 = 0.01
EF(day 1) 0.04 0.001
CPK(peak) 1.75 < 0.001
ACA IgM 0.02 = 0.01
ACA IgG 1.75 = 0.02
MDT 0.03 = 0.02
WMSI = Wall motion score index; EF = Ejection fraction; CPK = Creatine
phospho kinase; ACA = Anticardiolipin; MDT = Mitral E wave deceleration
time; NS = Non significant.
Table 4 Multiple regression analysis for LVT formation
and related parameters
Independent variables OR p value
Diabetes Mellitus 1.26 0.03
WMSI 1.95 0.001
MDT 1.67 0.001
ACA IgM 1.27 0.04
ACA IgG 1.41 0.03
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cant proportion recieved no PCI neither thrombolysis.
Therefore subjects in this study are not representative
for contemporary treatment of acute anterior MI in
r e s p e c tt oP C Ie r a .B u ti ts h o u l db en o t e dt h a t ,P C I
availability is still limited in many centers worldwide,
especially in developing countries and pain to needle
time is still extended in many areas. Our study popula-
tion consists of a significant number of patients referred
from other centers and other cities. For that reason
many patients could not recieve reperfusion therapy due
to late admission. This mightb et h eo n eo ft h el e a d i n g
causes of high incidence of LVT in our study.
Higher mortality has been reported in patients with
left ventricular thrombi after infarction, especially when
these develop within the first 48 hours after infarction
[1,2]. Left ventricular thrombosis is associated with
increased embolism risk [12,23,24]. Therefore, better
understanding of the circumstances in which left ventri-
cular thrombosis occurs may influence patient manage-
ment. As mentioned before, in our study four embolic
cerebrovascular accidents developed in the group with
LVT during the 6-month follow-up period though they
were under ASA and warfarin therapy. Two of them
died. Any cerebrovascular event was not observed in
patient group without thrombus. Six-month mortality of
patients was 16.66%(5/30) with LVT, and 5%(2/40) with-
out LVT(P < 0.001).
Prospective echocardiographic studies investigating the
effect of thrombolytic therapy on thrombus formation
after myocardial infarction revealed controversial results.
Some of them did not demonstrate a reduction of LVT
incidence after thrombolytic therapy [25], while some
other studies showed that thrombolytic therapy, by pre-
serving the left ventricular function, reduced LVT inci-
dence [26-29]. In our study, thrombolytic therapy(either
tPa or streptokinase) has administrated to 40 patients.
LVT was observed in 16 of them(40%). Thrombolytic
therapy was not given to 25 patients, and LVT was
observed in 12 of them (48%). Of 5 patients undergoing
primary PCI, 2 developed LVT(40%). Although throm-
bolytic therapy seems to reduce LVT incidence in our
study, it is not statistically significant. In the modern
era, there is widespread use of reperfusion therapies
such as thrombolysis and primary PCI for the manage-
ment of AMI. In recent years, primary PCI with stenting
has become the reperfusion therapy of choice for AMI
in institutions with emergency cardiac catheterization
facilities. Primary PCI achieves full and sustained reper-
fusion, which promotes early recovery of the infarcted
myocardium and may therefore theoretically decrease
the incidence of LV thrombosis. Karla et al. in their ret-
rospective study found that, the incidence of LVT
among anterior MI patients treated with primary PCI
was 10% [30]. In a recent study from Rabbani et al. inci-
dence of LVT remains high despite PCI for acute ante-
rior wall MI(35%) [31].
In our study, multivariate analysis showed that; dia-
betes mellitus, higher WMSI, lower MDT, higher ACA
IgM and IgG levels were independent predictors of LVT
formation. In many studies, it is noted that higher
WMSI is associated with worse prognosis and high risk
of LVT formation [4,13,32,33]. WMSI shows severity of
left ventricular systolic dysfunction, so it is reasonable
to see high incidence of LVT in patients with higher
WMSI. A MDT of >130 ms was classified as nonrestric-
tive, and < 130 ms was defined as restrictive. This cut
off point has been shown to be consistent with restric-
tive hemodynamics and a powerfull independent predic-
tor of unfavorable outcome after acute myocardial
infarction [33,34]. The size of infarct zone has been
shown to influence the diastolic filling pattern, with
large infarcts exhibiting a restrictive filling pattern
[35,36]. Therefore a short MDT, indicative of a restric-
tive filling pattern, might simply reflect an increasing
infarct size and consequently a higher risk of left ventri-
cular dilatation.WMSI and MDT can be simply deter-
mined by 2-D and Doppler echocardiographic
examinations and if performed earlier after acute myo-
cardial infarction, they can help to identify high risk
patients for LVT development.
The association of anticardiolipin antibodies with
acute myocardial infarction has been shown in several
studies [37-40]. Our studyi su n i g u ea m o n go t h e r s
because it reveals association between anticardiolipin
antibodies and left ventricular thrombus formation for
the first time. Also some of the mentioned studies reveal
direct association of IgG type anticardiolipin antibodies
with acute myocardial infarction and inverse association
of IgM type anticardiolipin andibody levels with reccur-
ent cardiac events. But in our study, both IgM and IgG
type of antibodies seem to be associated with left ventri-
cular thrombus formation. Although we find a statistical
correlation between high IgG and high IgM ACA levels
and occurance of LVT, the actual values of IgG and
IgM ACA are not especially high. Thus the mean levels
of IgG ACA are about 20 GPLU and of IgM ACA about
10 MPLU. In patients who have antiphospholipid syn-
drome itself the levels are frequently far higher. The
combination of these modest antibody levels and exclu-
sion of patients in whom these ACA antibodies are
likely to be pathogenic(those with autoimmune disease,
arterial or venous thrombosis, collagen vascular disease
etc.) means that we are looking at importance of low-
level non-pathogenic ACA.
According to the current revised laboratory criteria for
APS [41], both lupus anticoagulant and aCL IgG and
IgM are maintained as laboratory APS criteria, and IgM
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revised criteria. Medium and high titers of IgG and IgM
aCL antibodies associate with clinical manifestations of
APS, and were selected as criteria in Sapparo [42] dur-
ing formulation of the international preliminary classifi-
cation criteria for APS. However, the threshold used to
distinguish moderate-high levels from low levels has no
Standard [43], and definition of the level that best corre-
sponds to the risk of clinical manifestations is difficult
[44]. Based on the best available evidence, and until an
international consensus is reached, the committee intro-
duced a clear statement on threshold for positive: > 40
GPL or MPL units. Referrence ranges of ACA assay in
our study for ACA IgM was <9.8 MPLU/ml and <13.3
MPLU/ml for IgG. Values above these cut-off points
were considered as elevated levels in this study. ACA
IgM and IgG levels were above these cut-off points for
34 and 45 patients respectively.
The question of whether anticardiolipin antibodies can
be induced in response to tissue necrosis that occurs in
myocardial infarction is unknown [45]. However, there
is clinical evidence that anticardiolipin antibodies pre-
cede the development of first MI and that anticardioli-
pin titers are stable for up to 3 months after MI [37,38].
These studies indicate that anticardiolipin antibodies are
not generated by tissue necrosis but rather they partici-
pate in the pathogenesis of MI. The relatively higher
levels of ACA in our study population can not answer
the question of whether anticardiolipin antibodies can
be induced in response to tissue necrosis that occurs in
myocardial infarction.
In a meta-analysis by Gali et al. [46] Lupus anticoagu-
lant was found to have the strongest association with
thrombosis, whereas only medium and high titers of
ACA IgG were linked to thrombosis. In our study, even
modest increase in the levels of both ACA IgG and IgM
were associated with left ventricular thrombosis. Prospec-
tive studies of large populations needed to explore this
association further. Numerous mechanisms have been
proposed to explain thrombus formation by antiphospho-
lipid antibodies, such as direct endothelial damage,
enhanced platelet aggregation, and inhibition of endogen-
ous anticoagulants. These antibodies, in the presence of
other hemostatic defects and impaired LV function, may
affect surface factors and promote clot formation.
Diagnostic coronary angiography was performed to 46
of 70 patients. There is a linear association between
number of diseased coronary artery and the LVT forma-
tion in our study. It is reasonable to see more severe LV
systolic dysfunction with multivessel coronary artery dis-
ease and thus LVT formation.
In summary, our data demonstrate that beside the low
ejection fraction, lower MDT and higher wall motion
score index, even modestly increased levels of ACA IgM
and ACA IgG are associated with LV thrombus forma-
tion in patients with anterior MI. Prospective, larger
scale studies will be a better guide for establishing the
impact of ACA on LVT formation.
Limitations
There are many limitations of this study. At first, it is
observational and therefore allows us to explore associa-
tions. It cannot provide casual evidences, but only states
hypotheses for further research. Moreover, the number
of participants is relatively small.
As stated in the text, the subjects in this study are not
representative for contemporary treatment of acute
anterior MI. A significant proportion of patients
admitted very late in the course of their MI and during
study period there were no enough arrangements for
primary PCI after office hours.
Colinearity between the diffent types of anticardiolipin
antibodies might have affect the results at multivariate
analysis. We did not repeat the ACA assays after a cer-
tain period in this study.
Several conceivable risk factors were found at multi-
variate analysis: diabetes mellitus, higher WMSI and
lower MDT. In this respect, an increase in mean level of
IgG and IgM aCL may appear as irrelevant findings in
relation to the poor standardization of the assay, its pos-
sible unreliable results close to acute events. But, it
must be stated that the main aim of this study is to
document all conceivable risk factors associated with
LVT formation.
Author details
1Istanbul University, Institute of Cardiology, Istanbul, Turkey.
2Bagcilar
Education and Research Hospital Cardiology Clinic, Istanbul, Turkey.
Authors’ contributions
EO enrolled the eligible patients and he was directly responsible for
collecting data and follow-up of patients. BO and HM performed the
echocardiographic examinations and checked the accuracy of obtained data.
HM participated in design and coordination of study. MHD performed the
statistical analysis. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 May 2010 Accepted: 19 September 2010
Published: 19 September 2010
References
1. Freidman MJ, Carlson K, Marcus FI, Woolfenden JM: Clinical correlation in
patients with acute myocardial infarction and left ventricular thrombus
detected by two-dimensional echocardiography. Am J Med 1982,
72:894-8.
2. Spirito P, Bellotti P, Chiarella F, Domenicucci S, Sementa A, Vecchioc :
Prognostic significance and natural history of left ventricular thrombi in
patients with acute myocardial infarction: a two-dimensional
echocardiographic study. Circulation 1985, 72:774-80.
3. Keating EC, Gross SA, Schlamowitz RA, et al: Mural thrombi in myocardial
infarctions: Prospective evalvation by two-dimensional
echocardiography. Am J Med 1983, 74:989-95.
Okuyan et al. Thrombosis Journal 2010, 8:15
http://www.thrombosisjournal.com/content/8/1/15
Page 6 of 74. Celik S, Baykan M, Erdal C, et al: Doppler -derived mitral deceleration time
as an early predictor of left ventricular thrombus after first anterior
acute myocardial infarction. American Heart J 2000, 140:772-777.
5. Hansten A, Norberg R, B Jörk HM, et al: Antibodies to cardiolipin in young
survivors of myocardial infarction: An association wth recurrent
cardiovascular events. Lancet 1986, 113.
6. Klemp P, Cooper RC, Strauss FJ, et al: Anticardiolipin antibodies in
ischaemic heart disease. Clin Exp Immunol 1988, 74:254-257.
7. Yılmaz E, Adalet K, Yılmaz G, et al: Importance of serum anticardiolipin
antibody levels in coronary heart disease. Clin Cardiol 1994, 17:117-121.
8. Thorp JM, Chescheir NC, Fann B: Postpartum myocardial infarction in a
patient with antiphospholipid syndrome. Am J Perinatol 1994, 11:1-3.
9. Sivasankaran S, Harikrishnan S, Tharakan JM: Left ventricular thrombi in the
presence of normal left ventricular function. Indian Heart J 2002,
54(2):196-8.
10. Willens HJ, Lowery MH, Lopez E, et al: Rapid resolution of left ventricular
thrombus in antiphospholipid syndrome. Echocardiography 2003,
20(1):67-70.
11. Bruce D, Bateman D, Thomas R: Left ventricular thrombi in a patient with
the antiphospholipid syndrome. Br Heart J 1995, 74(2):202-3.
12. Asinger RW, Mikell FL, Elsperger J, Hodges M: Incidence of left-ventricular
thrombosis after acute transmural myocardial infarction: serial
evaluation by two-dimensional echocardiography. N Engl J Med 1981,
305:297-302.
13. Neskovic AN, Marinkovic J, Bojic M, Popovic AD: Predictors of left
ventricular thrombus formation and disappearence after anterior wall
myocardial infarction. Eur Heart J 1998, 19:908-916.
14. Schiller NB, Shah PM, Crawford M, De Maria A, Devereux R, Feigenbaum H,
Gutgesell H, Reichek N, Sahn D, Schnittger I: For the American Society of
Echocardiography Commitee on standards, Subcommitee on
Quantitation of Two Dimensional Echocardiograms. Recommendations
for quantitation of the left ventricle by tow-dimensional
echocardiography. J Am Soc Echocardiogr 1989, 2:358-367.
15. Zhang Y, Takagawa J, Sievers RE, Khan MF, et al: Validation of the wall
motion score and myocardial performance indexes as novel techniques
to assess cardiac function in mice after myocardial infarction. Am J
Physiol Heart Circ Physiol 2007, 292:1187-92.
16. McGowan JH, Cleland JG: Reliability of reporting left ventricular systolic
function by echocardiography: a systematic review of 3 methods. Am
Heart J 2003, 146:388-97.
17. Vaarala O, Alfthan G, Jauhiainen M, Aho K, Palosuo T: Crossreaction
between antibodies to oksidized low-density lipoprotein and to
cardiolipin in systemic lupus erythematosus. Lancet 1993, 341:923-5.
18. Haris EN, Gharavi AE, Patel SP, Hughes GR: Evaluation of the anti-
cardiolipin antibody test: report of an international workshop held 4
April 1986. Clin Exp Immunol 1987, 68:215-22.
19. Austen WG, Edwards JE, Frye RL, et al: A reporting system on patients
evaluated for coronary artery disease. Report of the Ad Hoc Commitee
for Grading of Coronary Artery Disease, Council on Cardiovascular
Surgery, American Heart Association. Circulation 1975, 51:5-40.
20. Weinreich DJ, Burke JF, Pauletto FJ: Left ventricular mural thrombi
complicating acute myocardial infarction: long term follow-up with
serial echocardiography. Ann Intern Med 1984, 100:789-94.
21. Domenicucci S, Bellotti P, Chiarella F, Lugi G, Vecchio C: Spontaneus
morphologic changes in left ventricular thrombi: a prospective two-
dimensional echocardiographic study. Circulation 1987, 75:737-43.
22. Visser CA, Kan G, Meltzer RS, Like I, Durrer D: Long-term follow-up of left
ventricular thrombus after acute myocardial infarction: a two-
dimensional echocardiographic study in 96 patients. Chest 1984,
86:532-6.
23. Jordan RA, Miller RD, Edwards JE, Parker RL: Thromboembolism in acute
and healed myocardial infarction. Circulation 1952, 6:1-6.
24. Cabin HS, Roberts WC: Left ventricular anevrysm, intraanevrysmal
thrombus and systemic embolus in coronary heart disease. Chest 1980,
77:586-90.
25. Held AC, Gore JM, Paraskos J, et al: Impact of trombolytic therapy on left
ventricular mural thrombi in acute myocardial infarction. Am J Cardiol
1988, 62:310-1.
26. Eigler N, Maurer G, Shah PK: Effect of early systemic thrombolytic therapy
on left ventricular thrombus formation in acute anterior myocardial
infarction. Am J Cardiol 1984, 54:261-3.
27. Bhatnagar SK, Yusuf AR, et al: Effects of intravenous recombinant tissue-
type plasminogen activator therapy on the incidence and associations
of left ventricular thrombus in patients with first Q wave anterior
myocardial infarction. Am Heart J 1991, 122:1251-6.
28. Lupi G, Domenicucci S, Chiarelli F, et al: Influence of thrombolytic
treatment followed by full dose anticoagulation on the frequency of left
ventricular thrombi in the acute anterior myocardial infarction. Am J
Cardiol 1989, 64:588-90.
29. Natarajan D, Hotchandani RK, Nigam PD: Reduced incidence of left
ventricular thrombi with intravenous streptokinase in acute myocardial
infarction: prospective evaluation by cross-sectional echocardiography.
Int J Cardiol 1988, 20:201-7.
30. Kalra A, Kyung Jang-IK: Prevelance of early left ventricular thrombus after
primary coronary intervention for acute myocardial infarction. J
Thrombosis and Thrombolysis 2000, 10:133-136.
31. Rabbani EL, Waksmonski C, Iqbal NS, Stant J, et al: Determinants of left
ventricular thrombus formation after primary percutaneous coronary
intervention for anterior wall myocardial infarction. J Thrombosis and
Thrombolysis 2008, 25:141-145.
32. Nishimura RA, Tajik AJ, Shub C, Miller FA, Ilsturp DM, Harrison CE: Role of
tow-dimensional echocardiography in the prediction of in-hospital
complications after acute myocardial infarction. J Am Coll Cardiol 1984,
4:1080-1087.
33. Oh JK, Ding ZP, Gersh BJ, et al: Restrictive left ventricular diastolic filling
identifies patients with heart failure after acute myocardial infarction. J
Am Soc Echocardiogr 1992, 5:497-503.
34. Nijland F, Kamp O, Karreman AJP, et al: Prognostic implications of
restrictive left ventricular filling in acute myocardial infarction: a serial
Doppler echocardiographic study. J Am Coll Cardiol 1997, 30:1618-24.
35. Popovic AD, Neskovic AN, Marinkovic J, et al: Serial assesment of left
ventricular chamber stiffness after acute myocardial infarction. Am J
Cardiol 1996, 777:361-4.
36. Pipilis A, Meyer TE, Ormerod D, et al: Early and late changes in left
ventricular filling after acute myocardial infarction and the effect of
infarct size. Am j Cardiol 1992, 70:1397-401.
37. Zuckerman E, Toubi E, Shiran A, et al: Anticardiolipin antibodies and acute
myocardial infarction in non-systemic lupus erythematosus patients: a
controlled prospective study. Am J Med 1996, 171:381-386.
38. Vaarala O, Manttari M, Manninen V, et al: Anticardiolipin antibodies and
risk of myocardial infarction in a prospective cohort of middle-aged
men. Circulation 1995, 91:23-27.
39. Wu R, Nityanand S, Berglund L, et al: Antibodies against cardiolipin and
oxidatively modified LDL in 50-year-old men predict myocardial
infarction. Arterioscler Thromb Vasc Biol 1997, 17:3159-3163.
40. Bili A, Moss AJ, Francis CW, Zareba W, et al: Anticardiolipin antibodies and
recurrent coronary events: a prospective study of 1150 patients.
Thrombogenic Factors, and Recurrent Coronary Events Investigators.
Circulation 2000, 102(11):1258-63.
41. Miyakis S, Lockshin MD, Atsumi T, Branch DW, et al: International
Consensus statement on an update of the classification criteria for
definite antiphospholipid syndrome(APS). Journal of Thrombosis and
Haemostasis 2006, 4:295-306.
42. Wilson WA, Gharavi AE, Koike T, Lockshin MD, et al: International
consensus statement on preliminary classification criteria for definite
antiphospholipid syndrome. Arthritis Rheum 1999, 42:1309-11.
43. Levine JS, Branch DW, Rauch J: The antiphospholipid syndrome. N Engl J
Med 2002, 346:752-63.
44. Wong RC: Consensus guidelines for anticardiolipin antibody testing.
Thromb Res 2004, 114:559-71.
45. Vaarala O: Antiphospholipid antibodies and atherosclerosis. Lupus 1996,
5:442-447.
46. Gali M, Luciani D, Bertolini G, Barbui T: Lupus anticoagulants are stronger
risk factors for thrombosis than anticardiolipin antibodies in the
antiphospholipid syndrome: a systematic review of the literature. Blood
2003, 101:1827-32.
doi:10.1186/1477-9560-8-15
Cite this article as: Okuyan et al.: Risk factors for development of left
ventricular thrombus after first acute anterior myocardial infarction-
association with anticardiolipin antibodies. Thrombosis Journal 2010 8:15.
Okuyan et al. Thrombosis Journal 2010, 8:15
http://www.thrombosisjournal.com/content/8/1/15
Page 7 of 7